AR043258A1 - Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica - Google Patents
Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastricaInfo
- Publication number
- AR043258A1 AR043258A1 ARP040100556A ARP040100556A AR043258A1 AR 043258 A1 AR043258 A1 AR 043258A1 AR P040100556 A ARP040100556 A AR P040100556A AR P040100556 A ARP040100556 A AR P040100556A AR 043258 A1 AR043258 A1 AR 043258A1
- Authority
- AR
- Argentina
- Prior art keywords
- omeprazol
- formulation
- quick
- subject
- immediate release
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002496 gastric effect Effects 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- 230000001629 suppression Effects 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 4
- 208000010643 digestive system disease Diseases 0.000 abstract 4
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 3
- 239000000612 proton pump inhibitor Substances 0.000 abstract 3
- 210000004051 gastric juice Anatomy 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Métodos, kits, combinaciones y composiciones para tratar, prevenir o reducir el riesgo de desarrollar un trastorno o enfermedad gastrointestinal, o los síntomas asociados a, o relacionados con un trastorno o enfermedad gastrointestinal en un sujeto que lo necesita. Composición farmacéutica que comprende un agente inhibidor de la bomba de protones y un agente regulador del pH para la administración oral e ingestión por parte de un sujeto. Luego de su administración, la composición entre en contacto con el jugo gástrico estomacal y aumenta el pH del mismo a un pH que evita o inhibe sustancialmente la degradación ácida del agente inhibidor de la bomba de protones en el jugo gástrico y permite que se absorba una concentración sérica mensurable del agente inhibidor de la bomba de protones al suero sanguíneo del sujeto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44862703P | 2003-02-20 | 2003-02-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043258A1 true AR043258A1 (es) | 2005-07-20 |
Family
ID=32908619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040100556A AR043258A1 (es) | 2003-02-20 | 2004-02-23 | Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040248942A1 (es) |
EP (1) | EP1603537A4 (es) |
JP (1) | JP2006518751A (es) |
AR (1) | AR043258A1 (es) |
CA (1) | CA2517005A1 (es) |
TW (1) | TWI367759B (es) |
WO (1) | WO2004073654A2 (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050220870A1 (en) * | 2003-02-20 | 2005-10-06 | Bonnie Hepburn | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
US8993599B2 (en) * | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
CA2531566C (en) * | 2003-07-18 | 2013-05-07 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
CA2531564C (en) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
US20050249806A1 (en) * | 2004-02-10 | 2005-11-10 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug |
GB0403165D0 (en) * | 2004-02-12 | 2004-03-17 | Ct | Novel uses for proton pump inhibitors |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) * | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US7576216B2 (en) | 2004-07-30 | 2009-08-18 | Abbott Laboratories | Preparation of pyridonecarboxylic acid antibacterials |
WO2006110815A1 (en) * | 2005-04-11 | 2006-10-19 | Abbott Laboratories | Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs |
ES2371658T3 (es) | 2005-04-12 | 2012-01-05 | Sucampo Ag | Uso combinado de compuesto de prostaglandina e inhibidor de la bomba de protones para el tratamiento de trastornos gastrointestinales. |
US20060276500A1 (en) * | 2005-04-26 | 2006-12-07 | Phillips Jeffrey O | Compositions and methods for treating nocturnal acid breakthrough and other acid related disorders |
US7981908B2 (en) * | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
CN101247810A (zh) * | 2005-08-19 | 2008-08-20 | 安万特药物公司 | 催眠药与R(+)-α-(2,3-二甲氧基-苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇的组合及其治疗应用 |
SG184754A1 (en) * | 2005-12-28 | 2012-10-30 | Takeda Pharmaceutical | Controlled release solid preparation |
JPWO2007074910A1 (ja) * | 2005-12-28 | 2009-06-04 | 武田薬品工業株式会社 | 放出制御固形製剤 |
US8512761B2 (en) | 2006-01-27 | 2013-08-20 | Yale University | Fast acting inhibitor of gastric acid secretion |
DK1976532T3 (en) * | 2006-01-27 | 2016-02-01 | Univ Yale | FAST-ACTING INHIBITOR of gastric acid secretion |
ES2281292B1 (es) * | 2006-03-08 | 2008-06-16 | Quimica Sintetica S.A. | Nuevas sales de esomeprazol. procedimiento de preparacion y composiciones farmaceuticas que las comprenden. |
WO2008002567A2 (en) * | 2006-06-27 | 2008-01-03 | Alza Corporation | Methods of treating conditions by sustained release administration of benzimidazole derivatives |
EP1880716A1 (en) * | 2006-07-19 | 2008-01-23 | Sandoz AG | Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient |
WO2008012621A2 (en) * | 2006-07-25 | 2008-01-31 | Vecta, Ltd. | Compositions and meth0ds for inhibiting gastric acide secretion using derivatives of small dicarboxylic acids in combination with ppi |
WO2008016887A2 (en) * | 2006-07-29 | 2008-02-07 | Graceway Pharmaceuticals, Llc | Methods and pharmaceutical compositions to treat gastric acid disorders |
US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
US20080166423A1 (en) * | 2007-01-06 | 2008-07-10 | Renjit Sundharadas | Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity |
EP2252274A4 (en) | 2008-02-20 | 2011-05-11 | Univ Missouri | COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME |
JP2012531430A (ja) * | 2009-06-25 | 2012-12-10 | ポーゼン インコーポレイテッド | アスピリン療法を必要とする患者を治療するための方法 |
US20110124551A1 (en) * | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
WO2012106058A2 (en) | 2011-01-31 | 2012-08-09 | New Market Pharmaceuticals | Animal treatments |
CN104363901B (zh) | 2012-03-21 | 2017-03-22 | 美国考斯麦德生物科技有限公司 | 局部投与用于治疗疼痛、瘙痒症和炎症的含锶复合物 |
EP3505159B1 (en) | 2012-05-02 | 2020-11-04 | NewMarket Pharmaceuticals LLC | Pharmaceutical compositions for direct systemic introduction |
US20160250253A1 (en) * | 2013-09-24 | 2016-09-01 | Cosmederm Bioscience, Inc. | Strontium-containing complexes for treating gastroesophageal reflux and barrett's esophagus |
WO2015115586A1 (ja) * | 2014-01-31 | 2015-08-06 | 塩野義製薬株式会社 | 徐放性製剤 |
US11590165B2 (en) * | 2014-12-17 | 2023-02-28 | Bausch Health Companies Inc. | Formulations of calcium and phosphate for oral inflammation |
WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US11235002B2 (en) | 2015-08-21 | 2022-02-01 | Galleon Labs Llc | Strontium based compositions and formulations for pain, pruritus, and inflammation |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
KR102276547B1 (ko) * | 2020-09-04 | 2021-07-13 | 주식회사유한양행 | 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법 |
CN111870583B (zh) * | 2020-09-28 | 2020-12-18 | 上海翰森生物医药科技有限公司 | 一种注射用艾司奥美拉唑钠冻干制剂及其制备方法 |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4045564A (en) * | 1974-02-18 | 1977-08-30 | Ab Hassle | Benzimidazole derivatives useful as gastric acid secretion inhibitors |
IN148930B (es) * | 1977-09-19 | 1981-07-25 | Hoffmann La Roche | |
SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
US4472409A (en) * | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
SE8403179D0 (sv) * | 1984-06-13 | 1984-06-13 | Haessle Ab | New compounds |
US5246714A (en) * | 1985-10-11 | 1993-09-21 | Aktiebolaget Hassle | Drug preparation |
US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
SE8604566D0 (sv) * | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
NZ224252A (en) * | 1987-04-21 | 1991-09-25 | Erba Carlo Spa | An anthracycline glycoside and its preparation |
GB8809421D0 (en) * | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
JPH03505450A (ja) * | 1988-06-30 | 1991-11-28 | ジ・アップジョン・カンパニー | 胃腸病用の経皮抗分泌剤 |
IE64199B1 (en) * | 1988-12-22 | 1995-07-12 | Haessle Ab | Compound with gastric acid inhibitory effect and process for its preparation |
SE8804629D0 (sv) * | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
SE8804628D0 (sv) * | 1988-12-22 | 1988-12-22 | Ab Haessle | New compounds |
JP2694361B2 (ja) * | 1989-02-09 | 1997-12-24 | アストラ アクチエボラグ | 抗菌剤 |
EP0382489B1 (en) * | 1989-02-10 | 1994-11-17 | Takeda Chemical Industries, Ltd. | Use of benzimidazole derivatives as antibacterial agents |
SE8903563D0 (sv) * | 1989-10-26 | 1989-10-26 | Haessle Ab | A novel dissolution system |
US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
KR930000861B1 (ko) * | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
SE9002043D0 (sv) * | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
EP0593463B1 (en) * | 1990-06-20 | 1999-09-15 | Astra Aktiebolag | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
US5215874A (en) * | 1991-01-21 | 1993-06-01 | Fuji Photo Film Co., Ltd. | Silver halide photographic material having magnetic recording member |
US5244670A (en) * | 1991-04-04 | 1993-09-14 | The Procter & Gamble Company | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress |
WO1993006097A1 (en) * | 1991-09-20 | 1993-04-01 | Merck & Co., Inc. | Novel process for the preparation of anti-ulcer agents |
TW224049B (es) * | 1991-12-31 | 1994-05-21 | Sunkyong Ind Ltd | |
IS3990A (is) * | 1992-04-24 | 1993-10-25 | Ab Astra | Aðferð við að blanda saman efni sem hindrar flæðimagasýru og bakteríueyðandi efnis sem brotnar niður í súru umhverfi |
US5504082A (en) * | 1992-06-01 | 1996-04-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Pyridine compound and pharmaceutical compostions |
FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
US5447918A (en) * | 1992-07-27 | 1995-09-05 | Mccullough; Ricky W. | Gastrointestinal anti-irritant composition comprising sucralfate and methods of use |
SE9301489D0 (sv) * | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
DE69424487T2 (de) * | 1993-09-09 | 2001-01-18 | Takeda Chemical Industries Ltd | Formulierung enthaltend einen antibakteriellen und einen Antiulcus Wirkstoff |
US5935600A (en) * | 1993-09-10 | 1999-08-10 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing comestible unit and product therefrom |
AU7833194A (en) * | 1993-09-20 | 1995-04-10 | Procter & Gamble Company, The | Use of triclosan phosphates for the treatment of gastrointestinal disorders due to heliobacter infection |
ATE219931T1 (de) * | 1993-10-12 | 2002-07-15 | Mitsubishi Pharma Corp | Darmlösliche grannulatkörner enthaltende tablette |
TW280770B (es) * | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
CA2180535C (en) * | 1994-01-05 | 2004-03-23 | Lindberg, Per Lennart | A method for treatment of psoriasis, by omeprazole or related compounds |
SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
GB2290965A (en) * | 1994-07-11 | 1996-01-17 | Therapicon Srl | Multiple layer capsules for drugs |
SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
GB9423968D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
US5628981A (en) * | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
HRP960232A2 (en) * | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
US5945124A (en) * | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
PL326353A1 (en) * | 1995-10-17 | 1998-09-14 | Astra Pharma Prod | Pharmaceutically active quinozolinic compounds |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
SE9600071D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
US6169102B1 (en) * | 1996-06-25 | 2001-01-02 | Takeda Chemical Industries, Ltd. | Oxazolone derivatives and their use as anti-Helicobacter pylori agent |
US5766622A (en) * | 1996-08-14 | 1998-06-16 | The Procter & Gamble Company | Inhibiting undesirable taste in oral compositions |
CA2262595C (en) * | 1996-08-15 | 2005-10-18 | Losan Pharma Gmbh | Easy to swallow oral medicament composition |
US5885594A (en) * | 1997-03-27 | 1999-03-23 | The Procter & Gamble Company | Oral compositions having enhanced mouth-feel |
US5939091A (en) * | 1997-05-20 | 1999-08-17 | Warner Lambert Company | Method for making fast-melt tablets |
TW580397B (en) * | 1997-05-27 | 2004-03-21 | Takeda Chemical Industries Ltd | Solid preparation |
SE9702000D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
SI1037634T1 (sl) * | 1997-12-08 | 2006-02-28 | Altana Pharma Ag | Peroralna dajalna oblika, ki obsega inhibitor protonske crpalke (npr. pantoprazol) |
US6365180B1 (en) * | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
FR2774288B1 (fr) * | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
US20020039597A1 (en) * | 1998-04-20 | 2002-04-04 | Koji Ukai | Stabilized compositions containing benzimidazole-type compounds |
US6047829A (en) * | 1998-09-18 | 2000-04-11 | Westvaco Corporation | Unit dose packaging system (UDPS) having a child resistant locking feature |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US7111317B1 (en) * | 2000-03-24 | 2006-09-19 | Eastman Kodak Company | Method for providing image goods and/or services to a customer |
AU5248900A (en) * | 1999-06-18 | 2001-01-09 | Takeda Chemical Industries Ltd. | Quickly disintegrating solid preparations |
US6555139B2 (en) * | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
US7678387B2 (en) * | 2000-06-06 | 2010-03-16 | Capricorn Pharma, Inc. | Drug delivery systems |
US6572900B1 (en) * | 2000-06-09 | 2003-06-03 | Wm. Wrigley, Jr. Company | Method for making coated chewing gum products including a high-intensity sweetener |
WO2003000235A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
US20030050620A1 (en) * | 2001-09-07 | 2003-03-13 | Isa Odidi | Combinatorial type controlled release drug delivery device |
US20040146559A1 (en) * | 2002-09-28 | 2004-07-29 | Sowden Harry S. | Dosage forms having an inner core and outer shell with different shapes |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
FR2832311B1 (fr) * | 2001-11-21 | 2004-04-16 | Besins Int Belgique | Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations |
CA2531564C (en) * | 2003-07-18 | 2016-01-19 | Santarus, Inc. | Pharmaceutical composition for inhibiting acid secretion |
US8062664B2 (en) * | 2003-11-12 | 2011-11-22 | Abbott Laboratories | Process for preparing formulations of lipid-regulating drugs |
-
2004
- 2004-02-20 JP JP2006503768A patent/JP2006518751A/ja active Pending
- 2004-02-20 US US10/783,871 patent/US20040248942A1/en not_active Abandoned
- 2004-02-20 EP EP04713382A patent/EP1603537A4/en not_active Withdrawn
- 2004-02-20 CA CA002517005A patent/CA2517005A1/en not_active Abandoned
- 2004-02-20 TW TW093104283A patent/TWI367759B/zh not_active IP Right Cessation
- 2004-02-20 WO PCT/US2004/005170 patent/WO2004073654A2/en active Application Filing
- 2004-02-23 AR ARP040100556A patent/AR043258A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2004073654A3 (en) | 2005-01-13 |
US20040248942A1 (en) | 2004-12-09 |
EP1603537A2 (en) | 2005-12-14 |
JP2006518751A (ja) | 2006-08-17 |
CA2517005A1 (en) | 2004-09-02 |
WO2004073654A2 (en) | 2004-09-02 |
EP1603537A4 (en) | 2009-11-04 |
TWI367759B (en) | 2012-07-11 |
TW200509923A (en) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR043258A1 (es) | Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica | |
Kaddoura et al. | Burn injury: review of pathophysiology and therapeutic modalities in major burns | |
AU2015207919B2 (en) | Materials and methods for improving gastrointestinal function | |
AR038157A1 (es) | Formas de dosificacion de benzimidazoles sustituidos y su uso | |
ECSP17013617A (es) | combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid | |
ECSP17000643A (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol. | |
AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
WO2007115282A3 (en) | Use of ketogenic compounds for treatment of age-associated memory impairment | |
UY29274A1 (es) | Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida | |
ES2941460T3 (es) | Composición y método para mejorar la curación de heridas | |
MA30768B1 (fr) | Methodes d'administration d'agents hypoglycemiques a longue duree d'action | |
MY147391A (en) | Treatment of chronic kidney disease (ckd) subjects using lanthanum compounds | |
Nna et al. | Testicular and epididymal histology of rats chronically administered high doses of phosphodiesterase-5 inhibitors and tramadol | |
Salim | Sulphydryl-containing agents: a new approach to the problem of refractory peptic ulceration | |
Ebrahimi et al. | Post marketing surveillance on safety and effectiveness of ANGIPARS in treatment of diabetic foot ulcers | |
Sapoznikov et al. | Minidose aspirin and gastrointestinal bleeding—a retrospective, case–control study in hospitalized patients | |
De Jong et al. | Effects of chronic paroxetine pretreatment on (±)-8-hydroxy-2-(di-n-propyl-amino) tetralin induced c-fos expression following sexual behavior | |
Patel et al. | A Rare Case of “Paraquat Tongue” | |
MX2019011389A (es) | Una formulacion novedosa, complejo antiacido de omeprazol de liberacion inmediata para supresion rapida y sostenida de acido gastrico. | |
Molinari et al. | Role of vitamin D3 and alginates in prevention of NSAID-dependent cellular injury | |
McVary et al. | 1637: Sildenafil Improves Erectile Function and Urinary Symptoms in Men with Erectile Dysfunction and Concomitant Lower Urinary Tract Symptoms | |
Yamabe et al. | A new pharyngitis model using capsaicin in rats | |
AR048355A1 (es) | Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen | |
Hawkey | Non‐steroidal anti‐inflammatory drugs and the gastric mucosa: mechanisms of damage and protection | |
Pokhrel et al. | Effectiveness of iron-based phosphate binders in reduction of hyperphosphataemia in chronic kidney disease patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |